← All Black Diamond Therapeutics, INC filings

Black Diamond Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
BDTX
Black Diamond Therapeutics, INC
10-K: Black Diamond Therapeutics Reports 2024 Results, Prioritizes Lead Program BDTX-1535
Black Diamond Therapeutics focuses on advancing BDTX-1535, a brain-penetrant EGFR MasterKey inhibitor, after reporting its 2024 financial results and implementing a corporate restructuring.
NASDAQ
BDTX
Black Diamond Therapeutics, INC
10-K: Black Diamond Therapeutics Outlines Securities and Corporate Governance in 10-K Filing
Black Diamond Therapeutics' 10-K filing details the company's common and preferred stock structure, anti-takeover measures, and corporate governance policies.